Perspective - Journal of Clinical Oncology and Cancer Research (2023) Volume 6, Issue 2
Precision oncology: Revolutionizing cancer treatment strategies.Andrew berry*
Department of Surgery, the University of Western Australia, Perth, Australia
- *Corresponding Author:
- Andrew berry
Department of Surgery
The University of Western Australia
Received: 01-Apr-2023, Manuscript No.AACOCR-23-98123; Editor assigned: 04-Apr-2023, PreQC No.AACOCR-23-98123 (PQ); Reviewed: 18-Apr-2023, QC No.AACOCR-23-98123; Revised: 21-Apr-2023, Manuscript No.AACOCR-23-98123 (R); Published: 26-Apr-2023, DOI:10.35841/aacocr-6.2.137
Precision oncology, also known as personalized or targeted therapy, has revolutionized the field of cancer treatment by tailoring therapeutic approaches to the specific characteristics of an individual's tumor. Traditional cancer treatments, such as chemotherapy and radiation therapy, have been effective but often come with significant side effects and limited efficacy for certain types of cancers. Precision oncology aims to overcome these limitations by leveraging advanced technologies and genomic information to develop customized treatment plans. In this essay, we will explore the concept of precision oncology, its underlying principles, key technologies involved, and its impact on cancer treatment outcomes .
Precision oncology is based on the understanding that each patient's cancer is unique, and the optimal treatment approach should be tailored accordingly. The principles of precision oncology, Genomic profiling involves analyzing the genetic makeup of a tumor to identify specific mutations or alterations that drive its growth. This profiling helps identify potential therapeutic targets and guide treatment decisions.
Targeted therapies are drugs designed to specifically inhibit or block the activity of molecules or pathways involved in cancer growth. These therapies are selected based on the genetic alterations identified through genomic profiling. Biomarkers are specific molecules or characteristics that can be measured to assess the presence or progression of a disease. In precision oncology, biomarkers are used to identify patients who are likely to respond to a particular treatment or to monitor treatment response. Precision oncology recognizes that cancer is a complex disease with multiple molecular abnormalities. Combination therapies, which involve using multiple targeted therapies or combining targeted therapies with traditional treatments, aim to address the heterogeneity of cancer and improve treatment outcomes .
Several technologies have been instrumental in advancing precision oncology: Next-Generation Sequencing (NGS): NGS enables rapid and cost-effective sequencing of the entire genome or specific regions of interest. This technology has greatly facilitated genomic profiling and identification of actionable mutations in cancer patients. Liquid biopsies involve analyzing various biomarkers, such as circulating tumor DNA (ctDNA) or Circulating Tumor Cells (CTCs), from a patient's blood sample. Liquid biopsies provide a noninvasive and real-time assessment of tumor characteristics, enabling dynamic monitoring of treatment response and the detection of resistance mechanisms. Imaging plays a crucial role in precision oncology for accurate tumor detection, characterization, and monitoring. Advanced imaging modalities, such as Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT), provide detailed anatomical and functional information, aiding in treatment planning and response assessment.
AI and machine learning algorithms are being employed to analyze large-scale genomic and clinical data sets to identify patterns, predict treatment responses, and develop personalized treatment plans. AI also assists in image analysis and radiomics, allowing for improved tumor characterization and treatment response prediction. Precision oncology is a rapidly evolving field of cancer research that aims to provide individualized, targeted therapies to cancer patients. The traditional approach to cancer treatment has been to use a “onesize- fits-all” approach, where all patients with a particular type of cancer are treated in the same way. However, it is now widely recognized that cancer is a heterogeneous disease, and that individual tumors can differ significantly from one another in terms of their genetic makeup and response to treatment. Precision oncology seeks to leverage advances in genomic and molecular profiling technologies to identify specific molecular alterations driving a patient’s cancer, and to develop therapies targeted to those alterations .
The advent of Next-Generation Sequencing (NGS) has revolutionized our ability to identify the genetic alterations that drive cancer. NGS allows researchers to sequence large portions of the genome at once, providing a comprehensive view of the genetic landscape of a tumor. This information can be used to identify mutations, gene fusions, and other molecular alterations that are driving the growth of the tumor. In some cases, the identification of a specific driver alteration can lead to the development of a targeted therapy that is designed to inhibit the activity of that alteration. For example, the identification of activating mutations in the Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) has led to the development of several drugs that specifically target this receptor.
Another important aspect of precision oncology is the identification of biomarkers that can be used to predict a patient’s response to a particular therapy. Biomarkers are measurable characteristics of a patient or tumor that can be used to indicate the presence of a particular disease or the likely response to a particular therapy. In precision oncology, biomarkers are often used to identify patients who are most likely to benefit from a particular therapy, or to predict which patients are likely to experience side effects or develop resistance to a particular therapy.
There are several challenges that must be overcome in order to fully realize the potential of precision oncology. One of the biggest challenges is the identification of clinically actionable targets. While genomic profiling can identify hundreds or thousands of genetic alterations in a tumor, only a subset of these alterations are likely to be driving the growth of the tumor and are amenable to targeted therapy. It is therefore important to prioritize the identification of the most clinically relevant alterations, and to develop therapies that can effectively target these alterations.
Another challenge is the development of effective clinical trial designs for precision oncology. Traditional clinical trial designs, which enroll large numbers of patients with a particular type of cancer and treat them all with the same therapy, are not well-suited to the evaluation of targeted therapies. In precision oncology, smaller, more focused trials are often needed to evaluate the efficacy of a particular targeted therapy in a specific patient population .
Despite these challenges, precision oncology has already had a significant impact on cancer treatment. Several targeted therapies have been developed that have improved outcomes for patients with specific types of cancer. For example, the drug imatinib has dramatically improved survival rates for patients with Chronic Myeloid Leukemia (CML) by targeting the BCR-ABL fusion protein that drives the growth of CML cells. Similarly, the development of immune checkpoint inhibitors, which block the activity of proteins that prevent the immune system from attacking cancer cells, has led to significant improvements in survival rates for patients with several types of cancer.
In addition to targeted therapies, precision oncology has also led to the development of new diagnostic tools that can help clinicians identify patients who are most likely to benefit from a particular therapy. For example, the Oncotype DX test is a genomic test that can be used to identify breast cancer patients who are at low risk of recurrence and therefore do not need to undergo chemotherapy. This test has the potential to spare many women from the toxicity and side .
- Schwartzberg L, Kim ES, Liu D, et al. Precision oncology: who, how, what, when, and when not?. Am Soc Clin Oncol Educ Book. 2017;37:160-9.
- Chakravarty D, Gao J, Phillips S, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017;1:1-6.
- Senft D, Leiserson MD, Ruppin E, et al. Precision oncology: the road ahead. Trends Mol Med. 2017;23(10):874-98.
- Del Paggio JC, Berry JS, Hopman WM, et al. Evolution of the randomized clinical trial in the era of precision oncology. JAMA oncol. 2021;7(5):728-34.
- Park JJ, Hsu G, Siden EG, et al. An overview of precision oncology basket and umbrella trials for clinicians. CA: A Cancer J Clin. 2020;70(2):125-37.